- Capital Cube•last year
Capitalcube gives Alseres Pharmaceuticals, Inc. a score of 25.Our analysis is based on comparing Alseres Pharmaceuticals, Inc. with the following peers – Threshold Pharmaceuticals, Inc., Cortex Pharmaceuticals, Inc., Navidea Biopharmaceuticals, Inc., IMRIS Inc., Eli Lilly and Company, International Isotopes Inc., Synthetic Biologics, Inc., Fonar Corporation, iCAD, Inc. and General Electric Company (THLD-US, CORX-US, NAVB-US, IMRSQ-US, […] (Read more...) The post Alseres Pharmaceuticals, Inc. – Value Analysis (US OTC:ALSE) : October 23, 2015 appeared first on CapitalCube.
We're sorry this is all we were able to find about this topic.
Alseres Pharmaceuticals, Inc. (ALSE)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||0.00 - 0.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||N/A|
|Dividend & Yield||N/A (N/A)|